# Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

Study · id `cardio:ct-nct04724837` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04724837](<https://clinicaltrials.gov/study/NCT04724837>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04724837

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 542 participants.

## Technical summary

Registry record NCT04724837. Randomized; triple masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2023-06-01 (actual). Results posted on 2024-07-30.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 542 participants (enrolled count; ClinicalTrials.gov record NCT04724837, source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)
- Started: 2021-04-28 (actual) (ClinicalTrials.gov record NCT04724837, source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)
- Primary completion: 2023-06-01 (actual) (ClinicalTrials.gov record NCT04724837, source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)
- Completion: 2023-06-01 (actual) (ClinicalTrials.gov record NCT04724837, source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)
- Results first posted: 2024-07-30 (ClinicalTrials.gov record NCT04724837, source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Croatia; Denmark; Georgia; Hungary; Italy; Japan; Malaysia; Netherlands; Poland; Slovakia; South Africa; Spain; Ukraine (ClinicalTrials.gov record NCT04724837, source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04724837-2024-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
- Acronym: ZENITH-CKD
- Condition: Chronic Kidney Disease
- Intervention (Drug): Zibotentan
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial (`cardio:pubmed-37931629`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 09f4082dfa0fbdf9cdeffd39860c80f45e9ebad41923fd403a57a57124d4299e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
